NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02260986,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,https://clinicaltrials.gov/study/NCT02260986,CHRONOS,COMPLETED,The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.,YES,Atopic Dermatitis,DRUG: Dupilumab|DRUG: Placebo (for Dupilumab)|OTHER: Topical Corticosteroid (TCS),"Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of ≥2 Points at Week 16, IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score ""0"" or ""1"" and a reduction from baseline of ≥2 points at Week 16 were reported., Baseline to Week 16","Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16, The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16., Baseline to Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported., Baseline to Week 16|Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥3 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported., Baseline to Week 16|Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of ≥2 Points at Week 52, IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of ""0"" or ""1"" and a reduction from baseline of ≥2 points at Week 52 were reported., Baseline to Week 52|Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 52, The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 52., Baseline to Week 52|Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\])., Baseline to Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 52 were reported., Baseline to Week 52|Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥3 points from baseline in weekly average of peak daily pruritus NRS score at Week 52 were reported., Baseline to Week 52|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 24, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 24 were reported., Baseline to Week 24|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 4 were reported., Baseline to Week 4|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 2 were reported., Baseline to Week 2|Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\])., Baseline to Week 16|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16, The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD., Baseline to Week 16|Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 16, BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined., Baseline to Week 16|Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16, SCORAD was a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease)., Baseline to Week 16|Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16, The DLQI was a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL., Baseline to Week 16|Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16, The POEM was a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\])., Baseline to Week 16|Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16, HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression., Baseline to Week 16|Percent Change From Baseline in Total Global Individual Signs Score (GISS) to Week 16, Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease)., Baseline to Week 16|Proportion of Topical Atopic Dermatitis Medication-Free Days Through Week 52, Proportion of topical AD medication-free days through Week 52 was calculated as the number of days that a participant used neither topical corticosteroid (TCS)/ topical calcineurin inhibitors (TCI) nor system rescue therapy divided by the study days of each period., Baseline to Week 52|Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 2, Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\])., Baseline to Week 2|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 52, The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD., Baseline to Week 52|Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 52, BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined., Baseline to Week 52|Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 52, SCORAD was a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease)., Baseline to Week 52|Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 52, Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease)., Baseline to Week 52|Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 52, The DLQI was a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL., Baseline to Week 52|Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 52, The POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\])., Baseline to Week 52|Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 52, HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire is scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression., Baseline to Week 52|Number of Flares Through Week 52, Atopic dermatitis (AD) flares were defined as worsening of the disease that required escalation/intensification of AD treatment. Number of flares occurred in the participants starting from first dose through Week 52 were reported., Baseline up to Week 52|Number of Serious Treatment Emergent Adverse Events (TEAEs) Leading to Study Drug Discontinuation Through Week 52, Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. A Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs., Baseline up to Week 52|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Week 52, Any untoward medical occurrence in a participants who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = ""Infection and Infestations"" or SOC = ""Skin and Subcutaneous Tissue Disorders"". Blinded adjudication was performed and finalized by the study medical monitor before database lock., Baseline up to Week 52|Number of Skin Infection TEAEs (Excluding Herpetic Infections) From Baseline Through Week 52, Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = ""Infection and Infestations"" or SOC = ""Skin and Subcutaneous Tissue Disorders"". Blinded adjudication was performed and finalized by the study medical monitor before database lock., Baseline up to Week 52|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52, Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = ""Infection and Infestations"" or SOC = ""Skin and Subcutaneous Tissue Disorders"". Blinded adjudication was performed and finalized by the study medical monitor before database lock., Baseline up to Week 52|Number of Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52, Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = ""Infection and Infestations"" or SOC = ""Skin and Subcutaneous Tissue Disorders"". Blinded adjudication was performed and finalized by the study medical monitor before database lock., Baseline up to Week 52","Change From Baseline in Sinonasal Outcome Test (SNOT-22) Score to Week 16, The SNOT 22 was a validated measure of health related quality of life in sinonasal disease. It was a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease) (lower scores represent better health related quality of life). The SNOT-22 was administered only to participants with chronic inflammatory conditions of the nasal mucosa and/or paranasal sinuses., Baseline to Week 16|Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score to Week 16, ACQ-5 questionnaire was a validated questionnaire comprising of 5 questions for asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath, and wheeze. Participants were asked to rate their asthma symptoms during the previous week on a 7-point scale as 0=no impairment, 6=maximum impairment. ACQ-5 score was the mean of the 5 questions and range between 0 (totally controlled) and 6 (severely uncontrolled) (a higher score indicated lower asthma control). The ACQ-5 questionnaire was administered only to the participants with a medical history of asthma., Baseline to Week 16",Regeneron Pharmaceuticals,Sanofi,ALL,"ADULT, OLDER_ADULT",PHASE3,740,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",R668-AD-1224,2014-09,2015-08,2016-10,2014-10-09,2017-04-30,2017-10-17,"Phoenix, Arizona, United States|Hot Springs, Arkansas, United States|Little Rock, Arkansas, United States|Encinitas, California, United States|Oceanside, California, United States|Palmdale, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Trumbull, Connecticut, United States|Edgewater, Florida, United States|Lake Worth, Florida, United States|Miami Lakes, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Alpharetta, Georgia, United States|Columbus, Georgia, United States|Savannah, Georgia, United States|West Dundee, Illinois, United States|Carmel, Indiana, United States|New Albany, Indiana, United States|Rockville, Maryland, United States|Ann Arbor, Michigan, United States|Bay City, Michigan, United States|Edina, Minnesota, United States|Fridley, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Verona, New Jersey, United States|Albuquerque, New Mexico, United States|Corning, New York, United States|New York, New York, United States|Smithtown, New York, United States|Stony Brook, New York, United States|Cincinnati, Ohio, United States|Norman, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Lake Oswego, Oregon, United States|Portland, Oregon, United States|Exton, Pennsylvania, United States|Hazleton, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Austin, Texas, United States|Dallas, Texas, United States|West Jordan, Utah, United States|South Burlington, Vermont, United States|Henrico, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Phillip, Australian Capital Territory, Australia|Kogarah, New South Wales, Australia|Benowa, Queensland, Australia|Dulwich, Queensland, Australia|Hectorville, South Australia, Australia|Carlton, Victoria, Australia|Surrey, British Columbia, Canada|Vancouver, British Columbia, Canada|Ajax, Ontario, Canada|Barrie, Ontario, Canada|Hamilton, Ontario, Canada|Markham, Ontario, Canada|North Bay, Ontario, Canada|Oakville, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|Drummondville, Quebec, Canada|Quebec, Canada|Hradec Kralove, Czechia|Nachod, Czechia|Praha 10, Czechia|Praha 5, Czechia|Svitavy, Czechia|Usti nad Labem, Czechia|Oroshaza, Békés, Hungary|Szolnok, Jász-Nagykun-Szolnok, Hungary|Veszprem, Veszprém, Hungary|Budapest, Hungary|Ancona, Italy|Bologna, Italy|Brescia, Italy|Novara, Italy|Pavia, Italy|Perugia, Italy|Roma, Italy|Kitakyushu, Fukuoka, Japan|Amagasaki, Hyôgo, Japan|Yokohama, Kanagawa, Japan|Kamimashiki-gun, Kumamoto, Japan|Saitama-shi, Saitama, Japan|Yaizu, Shizuoka, Japan|Koto-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Adachi-ku, Tôkyô, Japan|Chiyoda-ku, Tôkyô, Japan|Nakano-ku, Tôkyô, Japan|Nerima-ku, Tôkyô, Japan|Shibuya-ku, Tôkyô, Japan|Shinagawa-ku, Tôkyô, Japan|Shinjuku-ku, Tôkyô, Japan|Suginami-ku, Tôkyô, Japan|Fukuoka, Japan|Bucheon-si, Gyeonggido, Korea, Republic of|Suwon, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seodaemun-gu, Korea, Republic of|Uijeongbu-si, Korea, Republic of|Breda, Noord-Brabant, Netherlands|Amsterdam, Noord-Holland, Netherlands|Rotterdam, Zuid-Holland, Netherlands|Groningen, Netherlands|Utrecht, Netherlands|Dunedin, South Island, New Zealand|Auckland, New Zealand|Wroclaw, Dolnośląskie, Poland|Lublin, Lubelskie, Poland|Warszawa, Mazowieckie, Poland|Krakow, Małopolskie, Poland|Strzelce Opolskie, Opolskie, Poland|Iwonicz Zdroj, Podkarpackie, Poland|Bialystok, Podlaskie, Poland|Gdansk, Pomorskie, Poland|Poznan, Wielkopolskie, Poland|Szczecin, Zachodniopomorskie, Poland|Gdynia, Poland|Łódź, Łódzkie, Poland|Katowice, Śląskie, Poland|Skarzysko-Kamienna, Świętokrzyskie, Poland|Brasov, Braşov, Romania|Bucuresti, Bucureşti, Romania|Cluj-Napoca, Cluj, Romania|Craiova, Dolj, Romania|Targu Mures, Mureş, Romania|Barcelona, Cataluña, Spain|Alicante, Spain|Madrid, Spain|Dundee, Angus, United Kingdom|Edgbaston, Birmingham, United Kingdom|Glasgow, Glasgow City, United Kingdom|Sidcup, Kent, United Kingdom|Northwood, Middlesex, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Reading, United Kingdom|Salford, United Kingdom",
